Safety and Efficacy Study of Tozadenant to Treat End of Dose Wearing Off in Parkinson's Patients

PHASE3TerminatedINTERVENTIONAL
Enrollment

449

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

January 12, 2018

Study Completion Date

January 12, 2018

Conditions
Idiopathic Parkinson's Disease
Interventions
DRUG

tozadenant

DRUG

placebo

Trial Locations (71)

11725

Commack

12084

Albany

14602

Rochester

19019

Philadelphia

21201

Baltimore

24001

Roanoke

27517

Durham

28715

Asheville

30301

Atlanta

30805

Augusta

32034

Jacksonville

32601

Gainesville

33428

Boca Raton

33601

Tampa

35005

Birmingham

37011

Nashville

40502

Lexington

41073

Cincinnati

43460

Toledo

44101

Cleveland

48167

Farmington Hills

48302

West Bloomfield

48808

East Lansing

60007

Chicago

63101

St Louis

66012

Kansas City

74008

Tulsa

77001

Houston

80110

Englewood

85351

Sun City

90001

Los Angeles

91335

Reseda

92318

Loma Linda

93030

Oxnard

94043

Sunnyvale

98033

Kirkland

914203

Sacramento

06029

Vernon

02101

Boston

05401

Burlington

Unknown

Innsbruck

Vienna

Edmonton

Ottawa

Toronto

Brno

Choceň

Pardubice

Prague

Rychnov nad Kněžnou

Beelitz-Heilstätten

Berlin

Dresden

Haag in Oberbayern

Marburg

Ulm

Arcugnano

Cassino

Chieti

Grosseto

Pavia

Pisa

Rome

Salerno

Venice

Manresa

Sant Cugat del Vallès

Terrassa

Donostia / San Sebastian

Barcelona

Madrid

Sponsors
All Listed Sponsors
lead

Biotie Therapies Inc.

INDUSTRY